BioNTech has been granted a patent for compositions that produce an antibody or functional fragment targeting disialoganglioside-GD2. The patent also covers methods of treating or preventing diseases like cancer using the antibody, as well as a conjugate of the antibody fused to a diagnostic or therapeutic agent. The isolated antibody or fragment has specific amino acid sequences in its variable heavy and light chain domains. GlobalData’s report on BioNTech gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights BioNTech SE - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on BioNTech, Personalized cancer vaccines was a key innovation area identified from patents. BioNTech's grant share as of September 2023 was 35%. Grant share is based on the ratio of number of grants to total number of patents.

Patent granted for antibody against disialoganglioside-gd2 in cancer treatment

Source: United States Patent and Trademark Office (USPTO). Credit: BioNTech SE

A recently granted patent (Publication Number: US11760809B2) discloses isolated antibodies or antigen binding fragments that bind to GD2, a protein associated with certain types of cancer. The antibodies or fragments consist of a variable heavy chain (VH) domain and a variable light chain (VL) domain. The VH domain contains specific amino acid sequences, including residues 26-33, 51-58, and 97-109 of SEQ ID NO: 30, while the VL domain contains residues 27-37, 55-57, and 94-102 of SEQ ID NO: 32.

Claim 2 of the patent describes an alternative embodiment where the VH domain has the amino acid sequence of SEQ ID NO: 30 and the VL domain has the amino acid sequence of SEQ ID NO: 32. This provides flexibility in the design of the antibodies or fragments.

The patent also specifies that the antibodies can be human antibodies, indicating their potential for use in therapeutic applications. Additionally, the antibodies or fragments can be of various types, including Fab, Fab', F(ab')2, scFV, diabody, triabody, and minibody.

Furthermore, the antibodies can be monoclonal antibodies, which are highly specific and can be produced in large quantities for diagnostic and therapeutic purposes. They can also be of the IgG or IgM isotype, with IgG1 subclass being specifically mentioned.

The patent extends beyond the isolated antibodies themselves to include conjugates. These conjugates consist of the isolated antibodies or fragments conjugated or recombinantly fused to a diagnostic agent, detectable agent, or therapeutic agent. This opens up possibilities for targeted drug delivery and imaging applications.

Lastly, the patent covers pharmaceutical compositions comprising the isolated antibodies or fragments and a pharmaceutically acceptable carrier. This indicates the potential for the development of new cancer treatments based on the disclosed antibodies.

Overall, this granted patent provides valuable information on isolated antibodies or antigen binding fragments that specifically bind to GD2, offering potential applications in cancer diagnosis, therapy, and targeted drug delivery.

To know more about GlobalData’s detailed insights on BioNTech, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies